These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 9755436)
1. Dual-isotope protocol for indium-111 capromab pendetide monoclonal antibody imaging. Kelty NL; Holder LE; Khan SH J Nucl Med Technol; 1998 Sep; 26(3):174-7. PubMed ID: 9755436 [TBL] [Abstract][Full Text] [Related]
2. Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. Hardie AD; Rieter WJ; Bradshaw ML; Gordon LL; Young MA; Keane TE World J Urol; 2013 Dec; 31(6):1327-32. PubMed ID: 23595605 [TBL] [Abstract][Full Text] [Related]
3. Technical considerations for acquiring and processing indium-111 capromab pendetide images. Williams BS; Hinkle GH; Lamatrice RA; Fry JP; Loesch JA; Olsen JO J Nucl Med Technol; 1997 Sep; 25(3):205-16. PubMed ID: 9291068 [TBL] [Abstract][Full Text] [Related]
4. Using vascular structure for CT-SPECT registration in the pelvis. Hamilton RJ; Blend MJ; Pelizzari CA; Milliken BD; Vijayakumar S J Nucl Med; 1999 Feb; 40(2):347-51. PubMed ID: 10025845 [TBL] [Abstract][Full Text] [Related]
5. Progress in SPECT/CT imaging of prostate cancer. Seo Y; Franc BL; Hawkins RA; Wong KH; Hasegawa BH Technol Cancer Res Treat; 2006 Aug; 5(4):329-36. PubMed ID: 16866563 [TBL] [Abstract][Full Text] [Related]
6. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950 [TBL] [Abstract][Full Text] [Related]
7. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Rosenthal SA; Haseman MK; Polascik TJ Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670 [TBL] [Abstract][Full Text] [Related]
8. Possible false-positive metastatic prostate cancer on an In-111 capromab pendetide scan as a result of a pelvic kidney. Valliappan S; Joyce JM; Myers DT Clin Nucl Med; 1999 Dec; 24(12):984-5. PubMed ID: 10595486 [No Abstract] [Full Text] [Related]
9. Correction of photon attenuation and collimator response for a body-contouring SPECT/CT imaging system. Seo Y; Wong KH; Sun M; Franc BL; Hawkins RA; Hasegawa BH J Nucl Med; 2005 May; 46(5):868-77. PubMed ID: 15872362 [TBL] [Abstract][Full Text] [Related]
13. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Hinkle GH; Burgers JK; Neal CE; Texter JH; Kahn D; Williams RD; Maguire R; Rogers B; Olsen JO; Badalament RA Cancer; 1998 Aug; 83(4):739-47. PubMed ID: 9708939 [TBL] [Abstract][Full Text] [Related]
14. Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Sodee DB; Sodee AE; Bakale G Semin Nucl Med; 2007 Jan; 37(1):17-28. PubMed ID: 17161036 [TBL] [Abstract][Full Text] [Related]
15. Impact of fusion of indium-111 capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer. Schettino CJ; Kramer EL; Noz ME; Taneja S; Padmanabhan P; Lepor H AJR Am J Roentgenol; 2004 Aug; 183(2):519-24. PubMed ID: 15269050 [TBL] [Abstract][Full Text] [Related]